"13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol"@en . . "98.3%"@en . "# Korhonen T, Tolonen A, Uusitalo J, Lundgren S, Jalonen J, Laine K: The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15963096 # Gentile DM, Verhoeven CH, Shimada T, Back DJ: The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9864282 "@en . "Desogestrel"@en . . . "Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like desogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge."@en . "Following oral administration, the relative bioavailability of desogestrel, as measured by serum levels of etonogestrel, is approximately 84%. The absolute oral bioavailability is about 76%."@en . . . "Desogestrelum"@en . . . . . . "Humans and other mammals"@en . . . " "@en . . . . "27.8±7.2 hours"@en . . . . . . . . "54024-22-5"@en . . . . . . . . . . . . . . . "Symptoms of overdose include nausea and vaginal bleeding."@en . . . . . . . . "Cerazette"@en . . . "For the prevention of pregnancy in women who elect to use this product as a method of contraception."@en . "Klaus Nickisch, \"METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL.\" U.S. Patent US20130123523, issued May 16, 2013."@en . . . "A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents. [PubChem]"@en . . . . . . . . . "approved"@en . . .